BioStem Technologies, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BSEM | CELU | CLGN | MDXG | SVA.TO | HUMA | |
|---|---|---|---|---|---|---|
| Market cap | 21.47M | 26.25M | 12.18M | 466.96M | 39.65M | 125.01M |
| P/E (TTM) | 1.3 | — | — | — | 10.5 | — |
| Forward P/E | 4.0 | -1.4 | -10.8 | 30.0 | -3.5 | -1.8 |
| Price/book | 0.7 | -0.7 | 2.1 | 2.2 | -1.7 | 4.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −71.95% | −55.60% | −80.60% | −59.17% | −26.67% | −69.59% |
| Today | 0.00% | −1.02% | +2.92% | −1.54% | −8.70% | +2.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BSEM news ›[EFFECT] BioStem Technologies, Inc. SEC Filing
BioStem Technologies, Inc. SEC Filing (Oct 13, 2026) Stock Titan [EFFECT] BioStem Technologies, Inc. SEC Filing Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language…
BioStem Technologies Completes $3 Million Private Placement Financing
BioStem Technologies ( (BSEM) ) has provided an update. The most recent analyst rating on (BSEM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on BioStem Technologies stock, see the BSEM Stock Forecast…
BioStem Technologies sells $3M in equity offering
The offering’s first sale date was September 29, 2026, and it was reported under Rule 506(b). BioStem Technologies, Inc. reported $3,000,000 USD sold and $0 USD remaining to be sold in an offering of equity and options, warrants or other…
BioStem Technologies CEO exercises 250K share options
BioStem Technologies (OTC: BSEM) develops and manufactures placental-derived allografts for advanced wound care and regenerative therapies using its BioRetain® process. - [Form 4] BioStem Technologies, Inc. Insider Trading Activity BioStem…
BioStem Technologies’ CEO and COO invest $1M in cash through exercise of stock options
BioStem (BSEM) CEO & COO exercised options to buy 500,000 shares at $2.00. BioStem Technologies (BSEM) on Thursday announced its Chair and CEO, Jason Matuszewski, and COO, Andrew Van Vurst, each exercised a portion of their outstanding…
BioStem Secures $40 Million Equity Financing Facility
BioStem Technologies ( (BSEM) ) has provided an announcement. The most recent analyst rating on (BSEM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on BioStem Technologies stock, see the BSEM Stock…
UBS upgrades Sartorius Stedim Biotech to Buy
Sartorius Stedim Biotech is drawing particular attention on the Paris stock market (+4.59%, at 191.30) in a more cautious market that sees the SBF 120 down 0.17%. The stock is being supported by an upgrade from UBS. Published on…
BioAffinity Technologies, Inc. announced that it expects to receive $3.940766 million in funding
bioAffinity Technologies, Inc. announced that it has entered into a securities purchase agreement with an institutional investor to issue 8,462,027 pre-funded warrants at an issue price of $0.4657... announced that it has entered into a…
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Oct 08, 2026, 13:30 ET WallachBeth Capital, LLC is acting as sole placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $4 million before deducting placement agent fees and…
BioAffinity Technologies Prices $4 Million Registered Direct Offering
marketscreener.com Medical Equipment, Supplies & Distribution BioAffinity Technologies Prices $4 Million Registered Direct Offering Published on 10/08/2026 at 12:53 pm EDT
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com4
- stocktitan.net3
- theglobeandmail.com2
- globenewswire.com1
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.